▎ 摘　　要

NOVELTY - Liver cancer targeted medicine carrying graphene oxide composite material comprises doxorubicin (DOX) and lactobionic acid modified graphene oxide comprising graphene oxide (GO)- polyethyleneimine (PEI)- fluorescein isothiocyanate (FI)-polyethylene glycol (PEG)-lactobionic acid (LA), where the mass ratio of DOX and GO-PEI-FI-PEG-LA is 1:0.5-1:2. USE - Used as liver cancer targeted medicine carrying graphene oxide composite material. ADVANTAGE - The drug-loading composite material: has high pH-sensitivity and liver cancer cell targeting function; and is suitable for antitumor research. DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for preparing the composite material, comprising dissolving graphene oxide (GO)- polyethyleneimine (PEI)- fluorescein isothiocyanate (FI)-polyethylene glycol (PEG)-lactobionic acid (LA) composite in water, adding aqueous solution of doxorubicin (DOX), mixing uniformly, adjusting the pH, stirring to react for 3-4 hours, dialyzing, and freeze-drying.